We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

76 hedge funds and large institutions have $465M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

7% more funds holding

Funds holding: 71 → 76 (+5)

38% less capital invested

Capital invested by funds: $750M → $465M (-$285M)

Holders
76
Holders Change
+5
Holders Change %
+7.04%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
16
Increased
21
Reduced
19
Closed
11
Calls
$518K
Puts
–
Net Calls
+$518K
Net Calls Change
+$541K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$7.62M
2
RCM
RA Capital Management
Massachusetts
+$7.39M
3
O
OrbiMed
New York
+$2.15M
4
American Century Companies
American Century Companies
Missouri
+$1.17M
5
HF
HRT Financial
New York
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$13.7M
2
N
Natixis
France
-$11.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.14M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$5.14M
5
PHS
PFM Health Sciences
California
-$4.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$109M – – –
RCM
2
RA Capital Management
Massachusetts
$48M +$7.39M +671,092 +19%
O
3
OrbiMed
New York
$45.5M +$2.15M +195,700 +5%
NI
4
Nextech Invest
Switzerland
$33.9M – – –
VVA
5
Vida Ventures Advisors
Massachusetts
$30.9M – – –
BlackRock
6
BlackRock
New York
$23.1M +$90.1K +8,189 +0.4%
BC
7
Boxer Capital
California
$20.8M – – –
Viking Global Investors
8
Viking Global Investors
Connecticut
$20.5M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$16.4M -$5.14M -466,789 -24%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$16.3M -$7.14M -648,219 -31%
Citadel Advisors
11
Citadel Advisors
Florida
$12.8M +$125K +11,350 +1%
DM
12
Deerfield Management
New York
$11.1M – – –
FCMV
13
Foresite Capital Management V
California
$9.85M – – –
LCM
14
Lynx1 Capital Management
Puerto Rico
$7.8M +$7.62M +692,508 New
NHAS
15
Novo Holdings A/S
Denmark
$7.03M +$783K +71,108 +13%
HMC
16
Harvard Management Company
Massachusetts
$5.61M – – –
State Street
17
State Street
Massachusetts
$4.76M +$377K +34,224 +9%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$4.11M +$16.2K +1,471 +0.4%
RSCM
19
Rock Springs Capital Management
Maryland
$3.88M +$47.3K +4,300 +1%
American Century Companies
20
American Century Companies
Missouri
$3.6M +$1.17M +105,882 +50%
Federated Hermes
21
Federated Hermes
Pennsylvania
$3.47M – – –
FCOMV
22
Foresite Capital Opportunity Management V
California
$3.28M – – –
WP
23
Woodline Partners
California
$2.93M – – –
Northern Trust
24
Northern Trust
Illinois
$2.34M -$62.7K -5,700 -3%
EC
25
EcoR1 Capital
California
$1.97M – – –
1
2 3 4

KNTE Hedge Fund Activity: Q1 2022 in Review

76 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2022, worth a combined $465M — down 38% from $750M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new KNTE positions and 11 closed out — a net gain of 5 holders — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $7.62M. The largest seller was VR Adviser, exiting entirely with an estimated $13.7M sold.

  • 76 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2022, up from 71 in Q4 2021.
  • Funds reported $465M of Kinnate Biopharma Inc. Common Stock stock for Q1 2022, down 38% quarter-over-quarter.
  • 16 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2022 and 11 closed out, a net change of +5 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2022 was Lynx1 Capital Management, an estimated $7.62M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2022 was VR Adviser, an estimated $13.7M sold.

Based on aggregated 13F filings for Q1 2022.